• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Royalty Pharma plc (Amendment)

    10/4/22 4:30:28 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RPRX alert in real time by email
    SC 13D/A 1 brhc10042533_sc13da.htm SC 13D/A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*

    Royalty Pharma plc
    (Name of Issuer)
    Class A Ordinary Shares
    (Title of Class of Securities)
    G7709Q104
    (CUSIP Number)

    Juan Francisco Mendez, Esq.
    Simpson Thacher & Bartlett LLP
    425 Lexington Avenue
    New York, New York 10017
    (212) 455-2000
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    October 4, 2022
    (Date of Event Which Requires Filing of this Statement)
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. G7709Q104
    1
    NAMES OF REPORTING PERSONS
     
     
    M. Germano Giuliani
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Switzerland and of the United Kingdom
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    11,554,660
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    50,000
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    11,554,660
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    50,000
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    11,604,660
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    2.7%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     
     
    2

    CUSIP No. G7709Q104
    1
    NAMES OF REPORTING PERSONS
     
     
    Skyeline Management Ltd
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    British Virgin Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    8,077,140
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    8,077,140
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    8,077,140
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    1.8%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     

    3

    CUSIP No. G7709Q104
    1
    NAMES OF REPORTING PERSONS
     
     
    Avara Management Ltd
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    British Virgin Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    11,554,660
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    11,554,660
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    11,554,660
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    2.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     
     
    4

    CUSIP No. G7709Q104
    1
    NAMES OF REPORTING PERSONS
     
     
    MGG Strategic SICAF SIF S.A.  – MGG Strategic
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Luxembourg
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    22,390,000
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    22,390,000
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    22,390,000
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    5.1%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    5

    CUSIP No. G7709Q104
    1
    NAMES OF REPORTING PERSONS
     
     
    MGG Strategic SICAF SIF S.A.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Luxembourg
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    22,390,000
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    22,390,000
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    22,390,000
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    5.1%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
     
    6

    CUSIP No. G7709Q104
    1
    NAMES OF REPORTING PERSONS
     
     
    GG1978 SICAF SIF S.A. – GG Strategic
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Luxembourg
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    21,426,170
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    21,426,170
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    21,426,170
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    4.9%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    7

    CUSIP No. G7709Q104
    1
    NAMES OF REPORTING PERSONS
     
     
    GG 1978 SICAF SIF S.A.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Luxembourg
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    21,426,170
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    21,426,170
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    21,426,170
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    4.9%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    8

    CUSIP No. G7709Q104
    1
    NAMES OF REPORTING PERSONS
     
     
    GISEV Trustees Limited
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Guernsey
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    43,816,170 (1)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    43,816,170 (1)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    43,816,170 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    10.0%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     
    (1) The number of shares referenced herein include (i) 22,390,000 Class A Shares directly held by MGG Strategic SICAF SIF S.A. – MGG Strategic, a sub-fund of MGG Strategic SICAF SIF S.A., which is owned by the MGG Trust, for which GISEV Trustees Limited is the trustee; and (ii) 21,426,170 Class A Shares directly held by GG 1978 SICAF SIF S.A. – GG Strategic, a sub-fund of GG 1978 SICAF SIF S.A., which is owned by the GG Trust, for which GISEV Trustees Limited is the trustee.

    9

    CUSIP No. G7709Q104
    1
    NAMES OF REPORTING PERSONS
     
     
    Achille G. Severgnini
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Italy
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    43,816,170 (1)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    43,816,170 (1)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    43,816,170 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    10.0%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     
    (1) The number of shares referenced herein include (i) 22,390,000 Class A Shares directly held by MGG Strategic SICAF SIF S.A. – MGG Strategic, a sub-fund of MGG Strategic SICAF SIF S.A., which is owned by the MGG Trust, for which Achille G. Severgnini is the protector; and (ii) 21,426,170 Class A Shares directly held by GG 1978 SICAF SIF S.A. – GG Strategic, a sub-fund of GG 1978 SICAF SIF S.A., which is owned by the GG Trust, for which Achille G. Severgnini is the protector.

    10

    Explanatory Note

    This Amendment No. 3 amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission (the “SEC”) on June 29, 2020, as amended by Amendment No. 1 to Schedule 13D filed with the SEC on April 5, 2022, as amended by Amendment No. 2 to Schedule 13D filed with the SEC on August 11, 2022 (as amended, the “Schedule 13D”) with respect to the Class A Ordinary Shares, par value $0.0001 per share (“Class A Shares”) of Royalty Pharma plc, a company formed under the jurisdictions of England and Wales (the “Issuer”).  Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Schedule 13D.

    Item 4.
    Purpose of Transaction

    Item 4 of the Schedule 13D is hereby amended and supplemented with the following:

    On September 29, 2022, GG Strategic entered into a 10b5-1 sales plan (the “GG 10b5-1 Plan”) pursuant to which, over a period from November 14, 2022 through March 31, 2023 or an earlier date at which all Class A Shares under the GG 10b5-1 Plan have been sold, GG Strategic may sell up to 1,000,000 Class A Shares subject to certain pricing limits and volume limits, including pursuant to Rule 144 of the Securities Act of 1933, as amended.  The amount and timing of any sales, if any, may vary and will be determined based on market conditions, share price and other factors. The program will not require GG Strategic to sell any specific number of shares of Class A Shares or at all, and may be modified, suspended or terminated at any time without notice.

    On September 29, 2022, MGG Strategic entered into a 10b5-1 sales plan (the “MGG 10b5-1 Plan”) pursuant to which, over a period from November 14, 2022 through March 31, 2023 or an earlier date at which all Class A Shares under the MGG 10b5-1 Plan have been sold, MGG Strategic may sell up to 1,000,000 Class A Shares subject to certain pricing limits and volume limits, including pursuant to Rule 144 of the Securities Act of 1933, as amended.  The amount and timing of any sales, if any, may vary and will be determined based on market conditions, share price and other factors. The program will not require MGG Strategic to sell any specific number of shares of Class A Shares or at all, and may be modified, suspended or terminated at any time without notice.

     The foregoing descriptions of each of the GG 10b5-1 Plan and the MGG 10b5-1 Plan is qualified in its entirety by reference to each of the GG 10b5-1 Plan and the MGG 10b5-1 Plan, filed as Exhibit F and Exhibit G respectively, to this Schedule 13D and incorporated by reference herein.

    Item 5.
    Interest in Securities of the Issuer

    Item 5(a) – (c) of the Schedule 13D is hereby amended and restated in its entirety as follows:

    (a) and (b) The percentage of beneficial ownership in this Schedule 13D is based on an aggregate of 437,139,178 Class A Shares outstanding as of August 1, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on August 4, 2022.

    The aggregate number and percentage of shares of Class A Shares beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on rows 7 through 11 and row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference.

    As of the date hereof: (a) Skyeline directly holds 8,077,140 Class A Shares, (b) Avara directly holds 3,477,520 Class A Shares, (c) MGG Strategic directly holds 22,390,000 Class A Shares, (d) GG Strategic directly holds 21,426,170 Class A Shares, and (e) the spouse of M. Germano Giuliani directly holds 50,000 Class A Shares over which Mr. Giuliani may be deemed to have shared beneficial ownership.

    Collectively, the Reporting Persons may be deemed to beneficially own an aggregate of 55,420,830 Class A Shares, representing beneficial ownership over 12.7% of the outstanding Class A Shares.

    Skyeline is wholly-owned by Avara. Avara is wholly-owned by M. Germano Giuliani.

    MGG Strategic is a sub-fund managed and administered by MGG SICAF. A board of directors consisting of M. Germano Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by MGG SICAF. Each member of the board disclaims beneficial ownership over such shares. MGG SICAF is owned by the

    11

    MGG Trust of which M. Germano Giuliani is the beneficiary. The MGG Trust is the 100% economic owner of the shares held by MGG Strategic.

    GG Strategic is a sub-fund managed and administered by GG 1978 SICAF. A board of directors consisting of Giammaria Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by GG 1978 SICAF. Each member of the board disclaims beneficial ownership over such shares. GG 1978 SICAF is owned by the GG Trust, of which Giammaria Giuliani is the beneficiary (together with the MGG Trust, the “Trusts”). The GG Trust is the 100% economic owner of the shares held by GG Strategic. Each of M. Germano Giuliani and Giammaria Giuliani disclaim beneficial ownership over the shares beneficially owned by MGG Strategic and GG Strategic.

    The trustee of each of the Trusts is GISEV Trustees. The protector of each of the Trusts is Achille G. Severgnini, who has the power to remove and replace the trustee of each the Trusts.

    Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that any Reporting Person is the beneficial owner of the Class A Shares referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose and each of the Reporting Persons expressly disclaims beneficial ownership of such Class A Shares and any assertion or presumption that it or he and the other persons on whose behalf this statement is filed constitute a “group.”

    (c) Information with respect to transactions in the Class A Shares that were effected since the Schedule 13D last filed with the SEC by the Reporting Persons are set forth below, all of which were sales effected in the open market.

     
    Seller
     
    Trade Date
     
    Quantity
     
    Price per
    Share
     
    Range*
     
    Skyeline Management Ltd
     
    8/25/2022
     
    500
     
    $44.00
     
    N/A
     
    GG 1978 SICAF SIF – GG Strategic
     
    8/25/2022
     
    1,994
     
    $44.00
     
    N/A
     
    Skyeline Management Ltd
     
    9/7/2022
     
    261,881
     
    $42.6596
     
    $42.24 - $42.83
     
    GG 1978 SICAF SIF – GG Strategic
     
    9/7/2022
     
    250,000
     
    $42.5303
     
    $42.09 - $42.83
     
    Skyeline Management Ltd
     
    9/8/2022
     
    237,619
     
    $42.739
     
    $42.37 - $43.14
     
    GG 1978 SICAF SIF – GG Strategic
     
    9/8/2022
     
    248,006
     
    $42.8617
     
    $42.395 - $43.155
     
    MGG STRATEGIC SICAF SIF S.A. – MGG Strategic
     
    9/14/2022
     
    190,860
     
    $42.4816
     
    $42.275 - $42.87
     
    GG 1978 SICAF SIF – GG Strategic
     
    9/14/2022
     
    190,860
     
    $42.4821
     
    $42.275 - $42.88
     
    MGG STRATEGIC SICAF SIF S.A. – MGG Strategic
     
    9/15/2022
     
    154,154
     
    $42.2622
     
    $42.08 - $42.625
     
    GG 1978 SICAF SIF – GG Strategic
     
    9/15/2022
     
    154,154
     
    $42.2624
     
    $42.08 - $42.65
     
    MGG STRATEGIC SICAF SIF S.A. – MGG Strategic
     
    9/16/2022
     
    154,986
     
    $41.7208
     
    $41.325 - $42.06
     
    GG 1978 SICAF SIF – GG Strategic
     
    9/16/2022
     
    154,986
     
    $41.7217
     
    $41.32 - $42.06
     
    MGG STRATEGIC SICAF SIF S.A. – MGG Strategic
     
    9/19/2022
     
    232,185
     
    $41.50
     
    $40.995 - $41.79
     
    GG 1978 SICAF SIF – GG Strategic
     
    9/19/2022
     
    232,185
     
    $41.4999
     
    $40.99 - $41.77
     
    Skyeline Management Ltd
     
    9/20/2022
     
    130,330
     
    $41.0152
     
    $41.00 - $41.19
     
    MGG STRATEGIC SICAF SIF S.A. – MGG Strategic
     
    9/20/2022
     
    267,815
     
    $41.0196
     
    $41.00 - $41.55
     
    GG 1978 SICAF SIF – GG Strategic
     
    9/20/2022
     
    267,815
     
    $41.0201
     
    $41.00 - $41.61
     
    Skyeline Management Ltd
     
    9/21/2022
     
    125,697
     
    $41.2530
     
    $41.00 - $41.545
     
    Skyeline Management Ltd
     
    9/22/2022
     
    211,380
     
    $41.1681
     
    $41.00 - $41.36
     
    Skyeline Management Ltd
     
    9/28/2022
     
    32,593
     
    $41.05
     
    N/A

    12

    *The Reporting Persons undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

    Item 6.
    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    Item 6 of the Schedule 13D is hereby amended and supplemented as follows:

    The information provided or incorporated by reference in Items 3, 4 and 5 is hereby incorporated by reference herein.

    MGG Strategic Facility Agreement

    On September 20, 2022, MGG SICAF, acting solely in respect of its sub-fund MGG Strategic, entered into a deed of amendment and restatement relating to the MGG Facility Agreement, pursuant to which MGG Strategic increased its pledge of Class A Shares as collateral to secure its obligations under the MGG Facility Agreement to an aggregate of 17,880,000 Class A Shares  The maximum amount available for MGG Strategic under the Facility Agreement was also increased to $75 million in respect of the committed facility under the MGG Facility Agreement, and $75 million in respect of the uncommitted facility under the MGG Facility Agreement. The maturity date in respect of the committed facility under the MGG Facility Agreement is September 20, 2024, and in respect of the uncommitted facility under the MGG Facility Agreement is September 20, 2023, with the possibility of extension thereof in accordance with the terms of the MGG Facility Agreement.  Upon the occurrence of certain events that are customary for this type of facility, the lender may exercise its rights to require MGG Strategic to pre-pay the loan proceeds or post additional collateral, or foreclose on, and dispose of, the pledged securities in accordance with the MGG Facility Documents.

    Uncommitted and On Demand Credit Facility Agreement

    Skyeline amended its Facility Documents with J.P. Morgan SE, as lender, to lower the number of pledged Class A Shares used as collateral to secure its obligations under the Facility Agreement to 8,077,140 Class A Shares.  The maximum amount available for Skyeline to borrow under the Facility Agreement remains $50 million.

    Item 7.
    Materials to be Filed as Exhibits

    Item 7 of the Schedule 13D is hereby amended and supplemented as follows:

    Exhibit No.
    Description
     
       
    Exhibit F
    GG Strategic 10b5-1 Sale Plan Agreement
       
    Exhibit G
    MGG Strategic 10b5-1 Sale Plan Agreement
       
    Exhibit H
    Power of Attorney

    13

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: October 4, 2022
       
         
     
    MARIO GERMANO GIULIANI
         
     
    By:
    /s/ Achille G. Severgnini, Attorney-in-Fact
         
     
    SKYELINE MANAGEMENT LTD
     
    By: GISEV Family Office SA, Corporate Director
         
     
    By:
    /s/ Achille G. Severgnini
     
    Name:
    Achille G. Severgnini
     
    Title:
    Director
         
     
    AVARA MANAGEMENT LTD
     
    By: GISEV Family Office SA, Corporate Director
         
     
    By:
    /s/ Achille G. Severgnini
     
    Name:
    Achille G. Severgnini
     
    Title:
    Director
         
     
    MGG STRATEGIC SICAF SIF S.A. – MGG Strategic
         
     
    By:
    /s/ Achille G. Severgnini
     
    Name:
    Achille G. Severgnini
     
    Title:
    Director
         
     
    By:
    /s/ Marco Sterzi
     
    Name:
    Marco Sterzi
     
    Title:
    Director
         
     
    MGG STRATEGIC SICAF SIF S.A.
         
     
    By:
    /s/ Achille G. Severgnini
     
    Name:
    Achille G. Severgnini
     
    Title:
    Director
         
     
    By:
    /s/ Marco Sterzi
     
    Name:
    Marco Sterzi
     
    Title:
    Director


     
    GG 1978 SICAF SIF S.A. – GG STRATEGIC
         
     
    By:
    /s/ Achille G. Severgnini
     
    Name:
    Achille G. Severgnini
     
    Title:
    Director
         
     
    By:
    /s/ Marco Sterzi
     
    Name:
    Marco Sterzi
     
    Title:
    Director
         
     
    GG 1978 SICAF SIF S.A.
         
     
    By:
    /s/ Achille G. Severgnini
     
    Name:
    Achille G. Severgnini
     
    Title:
    Director
         
     
    By:
    /s/ Marco Sterzi
     
    Name:
    Marco Sterzi
     
    Title:
    Director
         
     
    GISEV TRUSTEES LIMITED
         
     
    By:
    /s/ Karen Ann Higgins
     
    Name:
    Karen Ann Higgins
     
    Title:
    Director
         
     
    ACHILLE G. SEVERGNINI
         
     
    /s/ Achille G. Severgnini



    Get the next $RPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RPRX

    DatePrice TargetRatingAnalyst
    6/3/2024$28.00Buy → Neutral
    UBS
    6/14/2022$47.00Buy
    UBS
    5/13/2022$53.00Sector Outperform
    Scotiabank
    4/27/2022$56.00Buy
    Goldman
    4/14/2022$50.00Neutral → Overweight
    JP Morgan
    4/6/2022$48.00Overweight
    Morgan Stanley
    10/29/2021$50.00Neutral → Buy
    Citigroup
    8/16/2021$51.00 → $46.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $RPRX
    Financials

    Live finance-specific insights

    See more
    • Royalty Pharma Reports First Quarter 2025 Results

      Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. "Our business momentum continued in the first quarter of 2025 as we delivered double-digit growth in Portfolio Receipts and raised our financial guidance," said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. "Guided by our dynamic capital allocat

      5/8/25 7:15:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Declares Second Quarter 2025 Dividend

      NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royal

      4/21/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025

      NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma Founded in 1996, Royalty Pharm

      4/17/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. "I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "Vlad's entrepreneurial approach and outstanding leadership skills, hon

      4/8/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

      NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experience, responsible for designing and delivering the firm's Human Resources (HR) agenda, including onboarding, colleague engagement, professional development, compensation and benefits. Previously, Molly held a number of global HR roles of increasing responsibility at QBE Insurance Group, Perpetual Limited and National Australia Bank. Molly received her Bachelor of Arts and Master of Applied Science deg

      7/24/24 8:30:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

      NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma's Senior Leadership Committee. Eric joins Royalty Pharma from Verisk, a global leader in data-driven analytic insights and solutions, where he was a Senior Vice President, Chief Data Officer and Chief Technology Officer, and a member of the Executive Leadership Team. During his tenure at Verisk, he led their migration to the cloud, mainframe modernization strategy and Data Governance and Data Strategy Team. Prior to Verisk, Mr. Schneider held senior IT leadership roles at Moody

      9/21/23 8:25:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Royalty Pharma plc

      10-Q - Royalty Pharma plc (0001802768) (Filer)

      5/8/25 9:14:25 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma plc filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Royalty Pharma plc (0001802768) (Filer)

      5/8/25 7:31:50 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Royalty Pharma plc

      DEFA14A - Royalty Pharma plc (0001802768) (Filer)

      4/11/25 9:15:25 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Royalty Pharma plc

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      11/8/24 3:15:49 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Royalty Pharma plc

      SC 13D/A - Royalty Pharma plc (0001802768) (Subject)

      7/29/24 4:30:11 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      2/13/24 10:17:30 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Royalty Pharma Reports First Quarter 2025 Results

      Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. "Our business momentum continued in the first quarter of 2025 as we delivered double-digit growth in Portfolio Receipts and raised our financial guidance," said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. "Guided by our dynamic capital allocat

      5/8/25 7:15:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • U.S. FDA Approves Second Drug Product Manufacturing Facility for ADSTILADRIN® (nadofaragene firadenovec-vncg)

      Ferring expands production of ADSTILADRIN with new Parsippany, NJ, facility, adding to existing manufacturing sites in Kuopio, Finland Capacity expansion and diversification of manufacturing footprint further ensures stable and sustainable supply to meet the anticipated growth in global demand for ADSTILADRIN Milestone prompts final $200 million payment from Royalty Pharma Ferring Pharmaceuticals announced today the U.S. Food and Drug Administration (FDA) approved a state-of-the-art drug product manufacturing hub in Parsippany, NJ, for its intravesical non-replicating gene therapy ADSTILADRIN® (nadofaragene firadenovec-vncg). The approval expands Ferring's manufacturing capabilities

      4/24/25 8:30:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Declares Second Quarter 2025 Dividend

      NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royal

      4/21/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Royalty Pharma downgraded by UBS with a new price target

      UBS downgraded Royalty Pharma from Buy to Neutral and set a new price target of $28.00

      6/3/24 9:17:33 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS resumed coverage on Royalty Pharma with a new price target

      UBS resumed coverage of Royalty Pharma with a rating of Buy and set a new price target of $47.00

      6/14/22 7:27:46 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Royalty Pharma with a new price target

      Scotiabank initiated coverage of Royalty Pharma with a rating of Sector Outperform and set a new price target of $53.00

      5/13/22 7:24:42 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO, Chairman of the Board Legorreta Pablo G. was granted 288,352 units of Class A Ordinary Shares, increasing direct ownership by 452% to 352,147 units (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      5/9/25 5:18:28 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Investments & CLO Lloyd George W. was granted 48,646 units of Class A Ordinary Shares (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      5/9/25 5:15:40 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & Vice Chairman Hite Christopher was granted 48,646 units of Class A Ordinary Shares (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      5/9/25 5:14:15 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care